Dihexa timeline: what research and user reports show
Dihexa is a synthetic angiotensin IV analog developed for brain penetration and studied in animal models of neurotrophic signaling. Its human evidence base is thinner than for more established nootropic peptides like Semax, which is worth stating plainly before any timeline.
What the research actually shows
Most controlled evidence is preclinical, focused on neurotrophic signaling in animal models. Reported human timelines are based on community reporting rather than controlled trials, which is a real limitation to weigh.
Weeks reported anecdotally
Where cognitive changes are reported, they are generally described as building slowly over several weeks rather than showing up acutely, unlike the same-day reports common with Semax or Selank.
Common questions
Why is Dihexa's evidence weaker than other nootropics on this site? It is a newer compound without the controlled human research base that older peptides like Semax and Selank have accumulated.
For mechanism, dosing reference and citations, see the Dihexa reference page.